儿童CAR-T细胞治疗的挑战与展望

doi:10.12372/jcp.2024.24e0578

Abstract

Abstract:

It has been more than 10 years since chimeric antigen receptor T cells (CAR-T) therapy were first used to treat children with relapsed acute lymphoblastic leukemia, and thousands of patients worldwide have benefited from it. CAR-T treatment has greatly improved the overall prognosis of relapsed and refractory pediatric acute lymphoblastic leukemia patients and is gradually changing the treatment history of relapsed and refractory pediatric hematological tumor patients. Currently, CAR-T treatment for children still faces some challenges, but overall, the prospects are extremely promising.

Key words: chimeric antigen receptor T cell, challenge, prospect, child

LI Benshang, YANG Liu. Challenges and prospects of CAR-T treatment for pediatric disease[J].Journal of Clinical Pediatrics, 2024, 42(7): 573-577.

References 40

[1]	Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies[J]. Front Immunol, 2023, 14: 1113882.
[2]	Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration[J]. J Clin Oncol, 2015, 33(27): 2938-2948.
[3]	Gupta A, Cripe TP. Immunotherapies for pediatric solid tumors: a targeted update[J]. Paediatr Drugs, 2022, 24(1): 1-12.
[4]	Wang F, Fu K, Wang Y, et al. Small-molecule agents for cancer immunotherapy[J]. Acta Pharm Sin B, 2024, 14(3): 905-952. doi: 10.1016/j.apsb.2023.12.010 pmid: 38486980
[5]	Cuesta-Mateos C, Alcaraz-Serna A, Somovilla-Crespo B, et al. Monoclonal antibody therapies for hematological malignancies: not just lineage-specific targets[J]. Front Immunol, 2017, 8: 1936. doi: 10.3389/fimmu.2017.01936 pmid: 29387053
[6]	Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far[J]. Nat Rev Clin Oncol, 2023, 20(6): 359-371. doi: 10.1038/s41571-023-00754-1 pmid: 37055515
[7]	Talleur AC, Qudeimat A, Métais JY, et al. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL[J]. Blood Adv, 2022, 6(21): 5737-5749.
[8]	Zhu M, Wu B, Brandl C, et al. Blinatumomab, a bispecific T-cell engager (BiTE®) for CD19^- targeted cancer immunotherapy: clinical pharmacology and its implications[J]. Clin Pharmacokinet, 2016, 55(10): 1271-1288.
[9]	Wang T, Tang Y, Cai J, et al. Coadministration of CD19- and CD22-directed chimeric antigen receptor T-Cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase Ⅱ trial[J]. J Clin Oncol, 2023, 41(9): 1670-1683.
[10]	Xiao X, Huang S, Chen S, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies[J]. J Exp Clin Cancer Res, 2021, 40(1): 367. doi: 10.1186/s13046-021-02148-6 pmid: 34794490
[11]	Siegler EL, Kenderian SS. Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies[J]. Front Immunol, 2020, 11: 1973. doi: 10.3389/fimmu.2020.01973 pmid: 32983132
[12]	Hines MR, Knight TE, McNerney KO, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome[J]. Transplant Cell Ther, 2023, 29(7): 438.
[13]	Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor CAR T-cell therapy: characteristics, management, and future directions[J]. J Allergy Clin Immunol Pract, 2022, 10(2): 460-466.
[14]	Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy[J]. Blood, 2023, 141(20): 2430-2442.
[15]	Zhang Y, Zhou F, Wu Z, et al. Timing of tocilizumab administration under the guidance of IL-6 in CAR-T therapy for R/R acute lymphoblastic leukemia[J]. Front Immunol, 2022, 13:914959.
[16]	Rainone M, Ngo D, Baird JH, et al. Interferon-γ blockade in CAR T-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis[J]. Blood Adv, 2023, 7(4): 533-536.
[17]	Manni S, Del Bufalo F, Merli P, et al. Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies[J]. Nat Commun, 2023, 14(1): 3423. doi: 10.1038/s41467-023-38723-y pmid: 37296093
[18]	Xu N, Yang XF, Xue SL, et al. Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells[J]. Biochem Biophys Res Commun, 2022, 595: 54-61.
[19]	Mestermann K, Giavridis T, Weber J, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells[J]. Sci Transl Med, 2019, 11(499): eaau5907.
[20]	Ventin M, Cattaneo G, Maggs L, et al. Implications of high tumor burden on chimeric antigen receptor T-Cell immunotherapy: a review[J]. JAMA Oncol, 2024, 10(1): 115-121.
[21]	Sterner RC, Sterner RM. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy[J]. Front Immunol, 2022, 13:879608.
[22]	Gu T, Hu K, Si X, et al. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment[J]. WIREs Mech Dis, 2022, 14(6): e1576.
[23]	Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL[J]. Bone Marrow Transplant, 2021, 56(3): 552-566.
[24]	Gatto L, Ricciotti I, Tosoni A, et al. CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap[J]. Front Oncol, 2023, 13: 1206983.
[25]	Nix MA, Mandal K, Geng H, et al. Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A/MLL1-rearranged B-ALL[J]. Cancer Discov, 2021, 11(8): 2032-2049. doi: 10.1158/2159-8290.CD-20-0242 pmid: 33727310
[26]	Leung KT, Cai J, Liu Y, et al. Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China[J]. Leukemia, 2024, 38(2): 250-257. doi: 10.1038/s41375-023-02089-3 pmid: 38001171
[27]	Zhao Z, Sadelain M. CAR T cell design: approaching the elusive AND-gate[J]. Cell Res, 2023, 33(10): 739-740. doi: 10.1038/s41422-023-00828-w pmid: 37221269
[28]	Coorens THH, Collord G, Treger TD, et al. Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy[J]. Nature Cancer, 2023, 4(8): 1095-1101.
[29]	Gu R, Liu W, Mei Y, et al. The impact of ZNF384 rearranged on antigen editing during treatment-specific selective pressures in adult B cell acute lymphoid leukemia[J]. Blood, 2023, 142: 4209.
[30]	De Bie J, Demeyer S, Gielen O, et al. BCR-ABL1 positive B-ALL can undergo T-cell lineage shift to become CD19 negative T-ALL[J]. HemaSphere, 2018, 2(3): e42.
[31]	Liang M, Gong D, Wang L, et al. PAX5 haploinsufficiency induced CD8+ T cells dysfunction or exhaustion by high expression of immune inhibitory-related molecules[J]. Cancer Treat Res Commun, 2021, 28: 100437.
[32]	Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas[J]. Nature, 2022, 603(7903): 934-941.
[33]	Bufalo FD, Angelis BD, Caruana I, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma[J]. N Engl J Med, 2023, 388(14): 1284-1295.
[34]	Maalej KM, Merhi M, Inchakalody VP, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances[J]. Mol Cancer, 2023, 22(1): 20. doi: 10.1186/s12943-023-01723-z pmid: 36717905
[35]	Ayala Ceja M, Khericha M, Harris CM, et al. CAR-T cell manufacturing: major process parameters and next-generation strategies[J]. J Exp Med, 2024, 221(2): e20230903.
[36]	Yang J, He J, Zhang X, et al. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study[J]. Blood Cancer J, 2022, 12(7): 104. doi: 10.1038/s41408-022-00694-6 pmid: 35798714
[37]	Lin H, Cheng J, Mu W, et al. Advances in universal CAR-T cell therapy[J]. Front Immunol, 2021, 12:744823.
[38]	Jo S, Das S, Williams A, et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing[J]. Nat Commun, 2022, 13(1): 3453. doi: 10.1038/s41467-022-30896-2 pmid: 35773273
[39]	Muller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up[J]. N Engl J Med, 2024, 390(8): 687-700.
[40]	Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases[J]. Lancet, 2023, 402(10416): 2034-2044. doi: 10.1016/S0140-6736(23)01126-1 pmid: 37748491

Challenges and prospects of CAR-T treatment for pediatric disease

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 40

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LU Jun. The clinical significance and management strategies of B cell aplasia following CD19 CAR-T cell therapy in pediatric patients [J]. Journal of Clinical Pediatrics, 2024, 42(7): 578-582.
[2]	SHANG Qianwen, ZHANG Yongzhan, LU Aidong, JIA Yueping, ZUO Yingxi, DING Mingming, ZHANG Leping, ZENG Huimin. The efficacy and safety of modified CLAG regimen for relapsed or refractory acute myeloid leukemia in children [J]. Journal of Clinical Pediatrics, 2024, 42(7): 589-594.
[3]	ZHAO Fenghua, ZHANG Yue, SUN Jin, YAN Shuangqin, LYU Lanqiu, MU Lijuan, YANG Jing, LUO Yan, YAN Dongmei, ZHAO Dongmei. Child-rearing problems of premature/low birth weight children aged 0 to 3 years: a multicenter cross-sectional study [J]. Journal of Clinical Pediatrics, 2024, 42(7): 606-612.
[4]	CHEN Zongzong, LI Xiaojing, HOU Chi, PENG Bingwei, WU Wenxiao, ZHU Haixia, WU Wenlin, TIAN Yang, CHEN Wenxiong. Clinical features and prognosis of immune-related brainstem encephalitis in children [J]. Journal of Clinical Pediatrics, 2024, 42(7): 626-630.
[5]	FENG Lian, HU Junlong, HUANG Hui, LI Xiaozhong, LI Yanhong. Predictive value of urinary CXCL10 for mortality risk of critically ill children in PICU [J]. Journal of Clinical Pediatrics, 2024, 42(7): 631-636.
[6]	CHEN Ye, ZHU Shanliang, YANG Shiwei, CHEN Jun, HUA Lichun, TANG Ying. The value of two-dimensional speckle tracking imaging in the assessment of left ventricular function in children with influenza A-related myocarditis [J]. Journal of Clinical Pediatrics, 2024, 42(7): 648-653.
[7]	WANG Huiying, TANG Jiazhong, SHANG Wenyuan, HUANG Jihong, LU Yanan, CHEN Sun. Analysis of factors influencing mechanical ventilation duration after surgery for congenital heart disease [J]. Journal of Clinical Pediatrics, 2024, 42(7): 654-658.
[8]	LI Niu, WANG Jian. Current status of database construction for rare diseases in children [J]. Journal of Clinical Pediatrics, 2024, 42(7): 663-666.
[9]	MA Tao, LU Jie, XU Hui, ZHAO Shunying, LI Huimin. Clinical characteristics of extrapulmonary tuberculosis in 473 children [J]. Journal of Clinical Pediatrics, 2024, 42(6): 491-496.
[10]	GONG Ling, SHU Chang, RAN Haibo. Clinical characteristics and treatment outcomes of connective tissue disease-associated interstitial lung disease in children [J]. Journal of Clinical Pediatrics, 2024, 42(6): 503-508.
[11]	LIANG Jiawei, MA Xiaohui, JIA Xuan. Study on the application value of the new Lake Louise criteria in children with myocarditis [J]. Journal of Clinical Pediatrics, 2024, 42(6): 526-532.
[12]	FAN Na, WANG Chunhui, ZHANG Anding, ZENG Lingchao, LI Yuanxia, LIN Yan, SHANG Lei, ZHANG Xinhui, HE Xiaobao, QI Ke, JIANG Xun. Correlation between functional constipation and the formation of appendiceal fecaliths in children with acute appendicitis [J]. Journal of Clinical Pediatrics, 2024, 42(6): 533-537.
[13]	MAO Meng, SHAO Jie, CHEN Jinjin, SHEN Lixiao. Interpretation of Catch-up growth in infants and young children with faltering growth: expert opinion to guide general clinicians [J]. Journal of Clinical Pediatrics, 2024, 42(5): 390-398.
[14]	XU Jiangshan, XU Xin, HE Shuang, LIU Qian, TIAN Jie, LYU Tiewei. Single center clinical analysis of radiofrequency ablation for children with cardiac enlargement and ventricular preexcitation [J]. Journal of Clinical Pediatrics, 2024, 42(5): 407-413.
[15]	LI Zhijuan, BAO Ying, HUANG Huimei, ZHANG Min, WANG Ying, NIU Yunhe, YANG Nan, SUO Lei, LIANG Nan. Clinical features and factors associated with diabetes mellitus in children-onset systemic lupus erythematosus [J]. Journal of Clinical Pediatrics, 2024, 42(5): 419-424.